CB1763, a highly selective, novel non-covalent BTK inhibitor, targeting ibrutinib-resistant BTK C481S mutant

被引：5
|
作者：
Asami, Tokiko
Kawahata, Wataru
Kashimoto, Shigeki
Sawa, Masaaki
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-B152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B152
引用
收藏
页数：2
相关论文
共 47 条
  • [1] Development of novel Btk inhibitor, CB988 targering ibrutinib-resistant Btk C481S mutant
    Kawahata, Wataru
    Asami, Tokiko
    Irie, Takayuki
    Iwata, Yasuhiro
    Kiyoi, Takao
    Sawa, Masaaki
    [J]. CANCER RESEARCH, 2017, 77
  • [2] Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
    Naeem, Aishath
    Utro, Filippo
    Wang, Qing
    Cha, Justin
    Vihinen, Mauno
    Martindale, Stephen
    Zhou, Yinglu
    Ren, Yue
    Tyekucheva, Svitlana
    Kim, Annette S.
    Fernandes, Stacey M.
    Saksena, Gordon
    Rhrissorrakrai, Kahn
    Levovitz, Chaya
    Danysh, Brian P.
    Slowik, Kara
    Jacobs, Raquel A.
    Davids, Matthew S.
    Lederer, James A.
    Zain, Rula
    Smith, C. I. Edvard
    Leshchiner, Ignaty
    Parida, Laxmi
    Getz, Gad
    Brown, Jennifer R.
    [J]. BLOOD ADVANCES, 2023, 7 (09) : 1929 - 1943
  • [3] PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
    Sun, Yonghui
    Zhao, Xingwang
    Ding, Ning
    Gao, Hongying
    Wu, Yue
    Yang, Yiqing
    Zhao, Meng
    Hwang, Jinseok
    Song, Yuqin
    Liu, Wanli
    Rao, Yu
    [J]. CELL RESEARCH, 2018, 28 (07) : 779 - 781
  • [4] PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
    Yonghui Sun
    Xingwang Zhao
    Ning Ding
    Hongying Gao
    Yue Wu
    Yiqing Yang
    Meng Zhao
    Jinseok Hwang
    Yuqin Song
    Wanli Liu
    Yu Rao
    [J]. Cell Research, 2018, 28 : 779 - 781
  • [5] Preclinical efficacy of the HSP90 inhibitor SNX-5422 in targeting C481S mutant BTK and ibrutinib resistant CLL
    Chen, Timothy L.
    Harrington, Bonnie
    Truxall, Jean
    Wasmuth, Ronni
    Lehman, Amy
    Orlemans, Eric
    Byrd, John C.
    Woyach, Jennifer A.
    Hertlein, Erin
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [6] Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
    Gomez, Eliana B.
    Isabel, Lippincott
    Rosendahal, Mary S.
    Rothenberg, Stephen M.
    Andrews, Steven W.
    Brandhuber, Barb J.
    [J]. BLOOD, 2019, 134
  • [7] REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK
    Guisot, Nicolas E. S.
    Best, Stuart A.
    Wright, Victoria
    Thomason, Andrew
    Woyach, Jennifer A.
    Mantel, Rose
    McClanahan, Fabienne
    Abet, Valentina
    Castagna, Diana
    Cousin, Peggy
    Emmerich, Juliette
    Ho, Kelvin
    Kelly, James Russell
    King-Tours, James
    Lyons, Kristina
    Muller, Melanie
    Refuerzo, Julienne
    Sargent, Louise
    Talab, Fatima
    Bingham, Matilda
    Phillips, Caroline
    Armer, Richard
    [J]. BLOOD, 2016, 128 (22)
  • [8] AS-1763: a highly potent, noncovalent and next generation BTK inhibitor for the treatment of patients with B-cell malignancies having C481S mutation in BTK
    Kawahata, Wataru
    Asami, Tokiko
    Kiyoi, Takao
    Irie, Takayuki
    Kashimoto, Shigeki
    Furuichi, Hatsuo
    Sawa, Masaaki
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [9] FCN-589, a novel, potent and selective BTK inhibitor, targets BTK C481S for the treatment of B-cell malignancies
    Lin, Shu
    Tan, Haohan
    Liu, Qihong
    Wang, Yunling
    Liu, Bin
    Li, Zhifu
    Chen, Zhifang
    Wang, Xianlong
    Zhao, Xingdong
    Jiang, Lihua
    Wang, Xilei
    Cheng, Tao
    Zhou, Jiashu
    Wang, Weibo
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [10] Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
    A Hamasy
    Q Wang
    K E M Blomberg
    D K Mohammad
    L Yu
    M Vihinen
    A Berglöf
    C I E Smith
    [J]. Leukemia, 2017, 31 : 177 - 185
12345